Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date
tags : Vaccine save search
BioNTech and Pfizer to Begin Testing Universal Coronavirus Vaccine
Published: 2022-06-29 (Crawled : 22:00) - biospace.com/
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
vaccine
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Published: 2022-06-29 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.99 |
|
Communications
|
| O: 1.06%
H: 0.0%
C: 0.0%
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: -4.58%
H: 0.0%
C: 0.0%
BNTX | $157.45 5.6% 0.1% |
|
Health Technology
|
| O: 3.2%
H: 4.97%
C: 1.76%
PFE A | $52.31 -0.23% -0.1% |
|
Health Technology
|
| O: 1.79%
H: 2.31%
C: 1.43%
covid-19 vaccine agreement
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV
Published: 2022-06-28 (Crawled : 01:00) - biospace.com/
ICVX | $6.41 11.87% 5.06% |
|
|
| O: 1.68%
H: 0.0%
C: 0.0%
ivx-121 candidate for topline vaccine positive results phase 1
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
Published: 2022-06-28 (Crawled : 13:00) - biospace.com/
VBIV | $0.8174 1.1% 3.03% |
|
Health Technology
|
| O: -6.85%
H: 1.74%
C: -7.07%
hepatitis for vaccine
COVID-19 Vaccine Leaders Make Progress on Omicron-Specific Boosters
Published: 2022-06-27 (Crawled : 14:20) - biospace.com/
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
SNYNF | News | $108.84 |
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
covid-19 vaccine
Clover’s COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous Booster
Published: 2022-06-27 (Crawled : 12:00) - biospace.com/
DVAX | News | $12.96 2.94% -0.64% |
|
Health Technology
|
| O: 0.29%
H: 3.41%
C: 1.63%
covid-19 candidate vaccine
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Published: 2022-06-25 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $108.84 |
|
Health Technology
| Email alert
Add to watchlist
BNTX | $157.45 5.6% 0.1% |
|
Health Technology
| Email alert
Add to watchlist
PFE A | $52.31 -0.23% -0.1% |
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.99 |
|
Communications
| Email alert
Add to watchlist
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
| Email alert
Add to watchlist
covid-19 vaccine response
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001
Published: 2022-06-24 (Crawled : 17:00) - globenewswire.com
DVAX | News | $12.96 2.94% -0.64% |
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
covid-19 valneva europe for vaccine vla2001 authorization
Sanofi-GSK COVID-19 Vaccine Candidate Effective Against Omicron
Published: 2022-06-24 (Crawled : 16:00) - biospace.com/
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
covid-19 candidate vaccine
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Published: 2022-06-24 (Crawled : 13:00) - biospace.com/
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
covid-19 vaccine trial results
Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate
Published: 2022-06-24 (Crawled : 11:00) - globenewswire.com
EBS | $31.83 2.55% 0.0% |
|
Health Technology
|
| O: 6.55%
H: 0.91%
C: -0.27%
av7909 fda candidate for vaccine application license
Press Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine
Published: 2022-06-24 (Crawled : 06:00) - globenewswire.com
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
covid-19 report vaccine
Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17
Published: 2022-06-23 (Crawled : 19:00) - prnewswire.com
NVAX | News M | $57.11 11.04% 0.91% |
|
Health Technology
|
| O: -0.06%
H: 0.5%
C: -0.21%
covid-19 for chmp vaccine authorization
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in Europe
Published: 2022-06-23 (Crawled : 13:20) - globenewswire.com
DVAX | News | $12.96 2.94% -0.64% |
|
Health Technology
|
| O: 0.52%
H: 6.31%
C: 6.23%
covid-19 valneva europe candidate for chmp vaccine authorization positive
Charles River and Ziphius Vaccines Collaborate to Manufacture saRNA-Based Vaccine
Published: 2022-06-23 (Crawled : 13:00) - biospace.com/
CRL | News | $218.83 2.27% 0.0% |
|
Commercial Services
|
| O: 0.24%
H: 5.94%
C: 5.04%
vaccine
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer
Published: 2022-06-23 (Crawled : 12:00) - biospace.com/
EVAX | $1.96 2.08% 0.0% |
|
Manufacturing
|
| O: 3.28%
H: 3.17%
C: -2.12%
evx-03 biotech vaccine dna program cancer
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
Published: 2022-06-23 (Crawled : 12:00) - prnewswire.com
SNGX | $0.6 1.67% |
|
Health Technology
|
| O: 8.64%
H: 3.23%
C: -2.9%
vaccine
BioNTech Starts Construction of First mRNA Vaccine Manufacturing Facility in Africa
Published: 2022-06-23 (Crawled : 11:00) - biospace.com/
SNY | News | $50.93 1.8% 1.26% |
|
Health Technology
|
| O: 1.85%
H: 0.0%
C: 0.0%
BNTX | $157.45 5.6% 0.1% |
|
Health Technology
|
| O: 1.77%
H: 7.45%
C: 6.98%
vaccine mrna construction
Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology
Published: 2022-06-21 (Crawled : 13:20) - biospace.com/
ANIX M | $3.0 -1.96% -2.61% |
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
research vaccine technology cancer publication
Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
Published: 2022-06-21 (Crawled : 12:00) - biospace.com/
PFE A | $52.31 -0.23% -0.1% |
|
Health Technology
|
| O: -0.44%
H: 0.0%
C: 0.0%
for vaccine
USA Holiday (Independence Day) in 2 days
Your saved searches
Save your searches and get alerts when important news are released.
Mentioned Today
APPN | News 4 | $47.15 -0.44% 4.22% |
|
Technology Services
ARQQ | News | $6.2 -1.74% -2.54% |
|
Information
CDNA | News | $22.38 4.19% 0.0% |
|
Health Technology
FNCTF | News | $11.99 |
|
Communications
HLF | News | $21.56 5.43% 0.0% |
|
Distribution Services
HYB | News | $9.16 0% |
|
Miscellaneous
NVAX | News 4 | $57.11 11.04% 0.91% |
|
Health Technology
OKTA | News 4 | $95.96 6.15% -0.61% |
|
Technology Services
OSCR | News | $4.57 7.53% 0.0% |
|
PEGA | News | $49.44 3.34% 0.0% |
|
Technology Services
PM | News 4 | $99.72 0.99% -0.07% |
|
Consumer Non-Durables
TDOC | News | $34.83 4.88% -0.4% |
|
Health Services
TILE | News | $12.695 1.24% 0.0% |
|
Producer Manufacturing
UL | News | $46.29 1.0% -0.02% |
|
Consumer Non-Durables
UNLYF | News | $45.67 |
|
Consumer Non-Durables